Corona update mers

3,664 views

Published on


BY:
DR.SATTI MOH’D SALEH

INFECTIOUS DISEASE PHYSICIAN
MEDICAL DIRECTOR
MEEQAT GENERAL HOSPITAL
CBAHI INFECTION CONTROL MEMBER

Published in: Education
0 Comments
6 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
3,664
On SlideShare
0
From Embeds
0
Number of Embeds
9
Actions
Shares
0
Downloads
274
Comments
0
Likes
6
Embeds 0
No embeds

No notes for slide

Corona update mers

  1. 1. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): BY: DR.SATTI MOH’D SALEH INFECTIOUS DISEASE PHYSICIAN MEDICAL DIRECTOR MEEQAT GENERAL HOSPITAL CBAHI INFECTION CONTROL MEMBER
  2. 2. CORONA VIRUS - CORONA DERIVED FROM LATIN ( MEANS CROWN OR HALO) DUE TO SHORT SPIKE LIKE PROJECTIONS (HE)
  3. 3. MERS CoV- 6 NEW TYPE OF CORONA VIRUS  - 2ND OF 4 SUB GROUP ALPHA- B-GAMA & DELTA  - RNA VIRUS  -ALPHA & BETA DESCEND FROM BAT GENE POOL  - DELTA & GAMA FROM AVIAN GENE POOL
  4. 4. NOVEL CORONA VIRUS NOVEL CORONA VIRUS REPORTED ON 24/9/2012 BY DR. ALI MOHAMMAD ZAKI  -ISOLATED & IDENTIFIED FROM PATIENT 60 YEARS OLD WITH ACUTE PNEUMONEA & ARF BY DR. ALI M. ZAKI -POSTED HIS FINDINGS
  5. 5. vb.nhr.com -
  6. 6. CoronavirusReplication of
  7. 7. MERS CoV NAMED AS NOVEL CORONA VIRUS OR SAUDI’S SARS LIKE CORONA VIRUS  - INTERNATIONAL COMMITTEE ON TOXONOMY OF VIRUS NAME IT AS MERS CoV
  8. 8. MERS Cases and Deaths, April - Present Current as of September , , AM EDT Countries Cases (Deaths) France 2 (1) Italy 3 (0) Jordan 2 (2) Qatar 5 (2) Saudi Arabia 90 (44) Tunisia 3 (1) United Kingdom (UK) 3 (2) United Arab Emirates (UAE) 6 (2) Total 114 (54
  9. 9. Countries With Lab-Confirmed MERS Cases April 2012 - Present •France •Italy •Jordan •Kuwait •Oman •Qatar •Saudi Arabia •Tunisia •United Kingdom (UK) •United Arab Emirates (UAE)
  10. 10. Globally, from September 2012 to date, WHO has been informed of a total of 198 laboratory-confirmed cases of infection with MERS-CoV, including 84 deaths
  11. 11. -Total number reported are 148 case. -Total death is 61 deaths 41.2% -Males are 80 and Females are 52 cases. -Saudi 110 and Non Saudi were 22. -Cases with known animal contacts are 20 out of 132 = 17.8 %. -Primary cases are 47 , 11 of them had contacts with animals = 23.4% date-to-Numbers Reported up
  12. 12. INTERNATIONAL ALARM FOR TWO REASONS: VIRUS OFTEN DEADLY  NO CLEAR TREATMENT
  13. 13. SOURCE UNKNOWN
  14. 14. SPECULATION- VIRUSESBAT     INTERMEDIATE HOST    & OTHERSCAMELS    MULTIPLE GEOGRAPHIC SITES (MULTIPLE ZOOTIC EVENTS)  
  15. 15. SOURCE - AFRICAN BATSU,AUSTRALIA? TO MIDDLE EAST S O R C E SOURCE
  16. 16. KNOWN FACTS* -HAS TROPISM TO NON CILIATED BROCHIAL EPITHELIAL CELLS (CONTRA TO OTHER VIRUSES  - CELLS THAT MERS INFECT WITHIN THE LUNGS FORM 20 % OF RESPIRATORY EPITHELIAL CELLS  - LARGE NUMBER OF VIRUSES NEEDED TO BE INHALED TO CAUSE INFECTION
  17. 17. Is this virus the same as the SARS virus? the samenotisnovel coronavirusNo. The virus that caused severe acute respiratory syndrome (SARS) in 2003. However, like the SARS virus, the novel coronavirus is most similar to those found in bats. CDC is still learning about this new virus.
  18. 18. Location of Bat Sampling Sites
  19. 19. INCUBATIONCoV-MERS period The available data suggest that symptoms have occurred up to 14 days after last exposure. 
  20. 20. SYMPTOMS: Fever Cough Chills Sore throat Myalgia Arthralgia followed by dyspnea May present with fever and diarrhea Followed by ARDS, septic shock, multiorgan failure
  21. 21. CLINICAL CASECoV-MERS definition A person with an acute respiratory infection, which may include fever (≥ 38°C , 100.4°F) and cough; AND Suspicion of pulmonary parenchymal disease (e.g., pneumonia or acute respiratory distress syndrome based on clinical or radiological evidence); AND History of travel from the Arabian Peninsula or neighboring countries* within 14 days. 
  22. 22. CDC Case Definitions: Probable Case •Any person who- –meets the criteria above for “Patient Under Investigation” and has clinical, radiological, or histopathological evidence of pulmonary parenchyma disease (e.g. pneumonia or ARDS), but no possibility of laboratory confirmation exists, either because the patient or samples are not available or there is no testing available for other respiratory infections, AND –is a close contact with a laboratory-confirmed case, AND –has illness not already explained by any other infection or etiology, including all clinically indicated tests for community-acquired pneumonia according to local management guidelines. •OR any person with- –severe acute respiratory illness with no known etiology, AND –an epidemiologic link to a confirmed MERS case. .
  23. 23. Confirmed Case •A person with laboratory confirmation of infection with MERS-CoV Positive PCR for confirmation
  24. 24. Confirmed cases of MERS-CoV (n=55) and history of travel from the Arabian Peninsula
  25. 25.  Check for  co – infection with other viruses  e.g.: H1N1,  bacterial infection,  fungal infection.
  26. 26. MERS-CoV CLOSE CONTACT definition A close contact* is defined as a person who: Did not use respiratory protection (N95 or higher level respirator); AND Shared the same airspace within 10 feet for at least 5 minutes. Examples of close contact include providing care for the case (e.g., a healthcare worker or family member), or having similar close physical contact; or stayed at the same place (e.g., lived with, visited) as the case during their infectious period.
  27. 27. First Reported MERS-CoV Case 60 year old Saudi man •Presented on June 13th with 7d h/o fever and cough; recent shortness of breath •Increasing blood urea nitrogen (BUN) and creatinine, starting day 3 of admission •White cell count normal on admission (but 92.5% neutrophils) and increased to a peak of 23,800 cells per cubic millimeter on day 10 with neutrophilia, lymphopenia, and progressive thrombocytopenia
  28. 28. First Case: Chest Radiographs Bilateral enhanced pulmonary hilar vascular shadows (more prominent on the left) and accentuated bronchovascular lung markings. Multiple patchy opacities in middle and lower lung fields Opacities more confluent and dense A: On admission B: 2 days later
  29. 29. Radiographs of Patient 2 B. 4 days after onset of illn Ground glass opacity and consolidation of left lower l . Consolidation of right upper lobe, 1 day after onset of illness C and D. Bilateral ground-glass opacities and consolidation, 7 days and 9 days after onset of illness, respectively
  30. 30. First Case Outcome •Patient developed acute respiratory distress syndrome (ARDS) and multiorgan dysfunction syndrome •Died June 24th •No close contacts with severe illnesses reported
  31. 31. Saudi Arabia Household Cluster •A cluster of 4 respiratory illnesses in a family who lived in an apartment –All males; ages 16-70y •All hospitalized •3 of 4 confirmed with MERS-CoV •3 of 4 patients with gastrointestinal symptoms: diarrhea, abdominal pain, anorexia) •2 deaths
  32. 32. Types of clusters 1) Older clusters post alhassa (contained) are in Eastren, Hasa, Aseer and Riyadh. 2) Resent Clusters started August, 17-12-/2013 (Almadina, Riyadh (hospitals), Hafralbatin)
  33. 33. MERS-CoV Outbreak in Saudi Arabia April – May 2013 •Al-Ahsa governorate in eastern region •Cluster currently being investigated •25 confirmed cases, 14 confirmed deaths •18 males, 7 females; Ages 14 - 94 years, median age: 58 •Initial cases associated with one hospital but now also: –Family contacts –Healthcare workers –Cases with no link to hospital
  34. 34. MERS CoV positive cases by sex and Nationalitya 0 20 40 60 80 100 120 Male Female Saudi Non Saudi 80 52 110 22
  35. 35. MERS CoV positive cases by sex and Nationality 0 20 40 60 80 100 120 Male Female Saudi Non Saudi 80 52 110 22
  36. 36. clusterAlMunawaraMadina-Al Resident 55 Dialysis (1) Date of Onset 17/8/2013 Male 56 date of 18/8/2013 HCW 74 years old male on HD Dea d cas e Alive 35 yon HD 89 y 54 y F 39 y M HC W
  37. 37. clusterAlbatinHafr 3 cases asymptomatic Age 26,16,7 2 cases asymptomatic Age 3 and 18 38 y of age male (son) 8/8/2013 79 y mother Cousin 47 y 23/8/2013 74 Mother the above Dead case Alive
  38. 38. MERS CoV cases by contact with animals and chronic disease total (111 cases) contact with animals 19 0 10 20 30 40 50 60 70 80 90 100 admitted animal contact no animal contact chronic disease no disease 19 92 88 23 - Camel 10 - Goat 2, - Cat 2, - Chicken 2, -Bat 2 , - Others 1
  39. 39.  It is not always possible to identify patients with MERS-CoV early because some have mild or unusual symptoms. For this reason, it is important that health-care workers apply standard precautions consistently with all patients – regardless of their diagnosis – in all work practices all the time. date-to-Reported up
  40. 40. Droplet precautions should be added to the standard precautions when providing care to all patients with symptoms of acute respiratory infection. Contact precautions and eye protection should be added when caring for probable or confirmed cases of MERS-CoV infection. Airborne precautions should be applied when performing aerosol generating procedures. precautions Reported date-to-up
  41. 41. HAND HYAGIENE  Gloves •Gowns •Eye protection (goggles or face shield) •Respiratory protection that is at least as protective as a fit-tested NIOSH-certified disposable N95 filtering face
  42. 42. Personal Protective Equipment (PPE) for Healthcare personnel (HCP) Recommended PPE should be worn by HCP upon entry into patient rooms or care areas. •Upon exit from the patient room or care area, PPE should be removed and either: –Discarded, or –For re-useable PPE, cleaned and disinfected according to the manufacturer’s reprocessing instructions.
  43. 43. Environmental Infection Control •Follow standard procedures, per hospital policy and manufacturers’ instructions, for cleaning and/or disinfection of: –Environmental surfaces and equipment –Textiles and laundry –Food utensils and dishware
  44. 44. Infection Control Recommendations for Hospitalized Patients •These recommendations are for hospitalized patients who meet the case definition and are based on the following issues: –Poorly characterized clinical signs and symptoms, and a suspected high rate of morbidity and mortality among infected patients –Unknown modes of transmission of MERS-CoV –Lack of a vaccine and chemoprophylaxis –Evidence of limited, not sustained, human-to- human transmission
  45. 45. Patient Placement Airborne Infection Isolation Room (AIIR) –If an AIIR is not available, the patient should be transferred as soon as is feasible to a facility where an AIIR is available. –Pending transfer, place a facemask on the patient and isolate him/her in a single-patient room with the door closed. –The patient should not be placed in any room where room exhaust is recirculated without high-efficiency particulate air (HEPA) filtration. •Once in an AIIR, the patient’s facemask may be removed. •When outside of the AIIR, patients should wear a facemask to contain secretions.
  46. 46. Patient Placement Limit transport and movement of the patient outside of the AIIR to medically-essential purposes. •Implement staffing policies to minimize the number of personnel who must enter the room.
  47. 47. Health-care providers are advised to maintain vigilance.
  48. 48.  - NO SUSTAINED TRANSMISSION IN COMMUNITY  - PEOPLE WITH COMORBIDITY OR IMMUNOSUPPRESSION INCREASE INFECTION, INCREASE COMPLICATION, INCREASE MORBIDITY PERSON TO PERSON TRANSMISSION (VERY LOW)
  49. 49. People at high risk  of severe disease due to MERS-CoV should avoid close contact with animals when visiting farms or barn areas where the virus is known to be potentially circulating. For the general public, when visiting a farm or a barn, general hygiene measures, such as regular hand washing before and after touching animals, avoiding contact with sick animals, and following food hygiene practices, should be adhered to.
  50. 50. Complications  Complications have included severe 1- pneumonia, acute respiratory distress syndrome 2- (ARDS) with multi-organ failure, 3- renal failure requiring dialysis, consumptive 4- coagulopathy and pericarditis.
  51. 51. The number of people who came for Umra this year 1434 – 2013 are: 5,138,301 NO cases Umra statistics During 1434
  52. 52. ADVISES IN HAJJ & UMRA FREQUENT HAND WASHING CONTACT WITH OTHERS NOT TO TOUCH EYE NOSE & MOUTH WITHOUT HAND WASHING COVER MOUTH, NOSE WITH TISSUES (NOT TO INFECT OTHERS ON COUGHING & SNEEZING)
  53. 53. CDC does not recommend that travelers change their plans because of MERS. However, the Saudi Arabia Ministry of Health has made special recommendations for travelers to Hajj and Umrah. Because of the risk of MERS, Saudi Arabia recommends that the following groups should postpone their plans for Hajj and Umrah this year: People over 65 years old Children under 12 years old Pregnant women People with chronic diseases (such as heart disease, kidney disease, diabetes, or respiratory disease) People with weakened immune systems People with cancer or terminal illnesses CDC encourages people traveling to Saudi Arabia to perform Hajj or Umrah to consider this advice. People who are concerned about MERS should discuss their travel plans with their doctor.
  54. 54. How Can Travelers Protect Themselves? Taking these everyday actions can help prevent the spread of germs and protect against colds, flu, and other illnesses: Wash your hands often with soap and water. If soap and water are not based hand-alcoholavailable, use an .sanitizer Avoid touching your eyes, nose, and mouth. Germs spread this way. Avoid close contact with sick people. Be sure you are up-to-date with all of your shots, and if possible, see your healthcare provider at least 4–6 weeks before travel to get any additional shots. . :If you are sick Cover your mouth with a tissue when you cough or sneeze, and throw the tissue in the trash. Avoid contact with other people to keep from infecting them.
  55. 55. Investigations  Chest x – ray findings:  Bilateral hailer infiltrate  Bilateral patchy infiltrate  Segmental or lobar opacity  Pleural effusion
  56. 56. Laboratory Testing Lower respiratory specimens (sputum, bronchoalveolar lavage, endotracheal) are a priority respiratory specimen for real time reverse transcription polymerase chain reaction (RT-PCR) testing •Respiratory (lower and upper tracts), stool, and serum specimens •Specimen collection at different times
  57. 57. Positive PCR for confirmation
  58. 58. Emergency Use Authorization •FDA issued an EUA on June 5, 2013, to authorize use of CDC's “Novel coronavirus 2012 real-time reverse transcription–PCR assay” to test for MERS-CoV in clinical respiratory, blood, and stool specimens. •Assay will be deployed to Laboratory Response Network (LRN) laboratories in all 50 states over the coming weeks.
  59. 59. Approach to Serology •Identify and generate candidate CoV antigens –Using proteins from similar bat viruses •Develop ELISA-based assay •Evaluate assay with an extensive panel of negative (specificity) and positive sera (sensitivity)
  60. 60. Therapeutics •No vaccines developed as of yet • antivirals identified as of yet •Treatment
  61. 61. USED IN MONKEY - SYMPTOMS, SLOW VIRAL GROWTH DAMAGE TO LUNGS, BREATHING (ONLY USED IN FEW MONKEYS WITHIN 8 HOURS OF INFECTIONS) U S E D I N M O N K E Y
  62. 62. Management:   Isolation: standard + droplet ±airborne precautions  Organ support  Prevention of complications
  63. 63. Empiric use of:  Broad spectrum antibiotic  Antiviral (oseltamivir)  Plus or minus antifungal  Lung protective ventilator  Strategies for ARDS  Treatment of complication (RENAL FAILURE)  Steroids (no benefits)  Treatment of HCAI
  64. 64. PATIENTA DYINGIF YOU HAVE ,SHOULD IT AS LAST EFFORTYOU TRY
  65. 65. FUTURE TREATMENT INTERFERON ALFA 2 + RIBAVERIN
  66. 66. USED IN MONKEY - SYMPTOMS, SLOW VIRAL GROWTH DAMAGE TO LUNGS, BREATHING (ONLY USED IN FEW MONKEYS WITHIN 8 HOURS OF INFECTIONS) U S E D I N M O N K E Y
  67. 67. Selection criteria: To be considered eligible for oral ribavirin and subcutaneous pegylated interferon therapy, the patient must fulfill ALL the following criteria: 1. Laboratory-confirmed MERS-CoV infection 2. Clinical and radiological evidence of pneumonia 3. The patient requires invasive or non-invasive ventilatory support or showing progressive hypoxemia 4. Approval by one consultants in Adult Infectious Diseases
  68. 68. Administration Protocol: ml/min50CrCl‡ >  Ribavirin 2000mg po loading  dose, followed by  1200mg po q8h for  4 days then 600mg  po q8h for 4-6 days
  69. 69. ml/min50-20CrCl  2000mg po loading  dose, followed by  600mg po q8h for 4  days then 200mg po  q6h for 4-6 days
  70. 70. CrCl <20 ml/min or on dialysis  2000mg po loading  dose, followed by  200mg po q6h for 4  days then 200mg po  q12h for 4-6 days
  71. 71. Pegelated interferon  Pegelated interferon  alfa 2a  180 mcg subcutaneously once per week (up to 2 weeks)
  72. 72. Monitoring:  1. Both ribavirin and Peg-interferon are associated with considerable potential adverse effects. In  addition to any clinical or laboratory monitoring that is dictated by the patient’s condition, the
  73. 73. following investigations are essential before starting  a. Complete blood count  b. Renal function  c. Liver function
  74. 74.  2. Conscious patients must have a formal psychiatric assessment if there is any clinical evidence  of psychosis or acute confusion  Changes to the treatment protocol:  1. Changes in the treatment protocol in response to toxicity or clinical developments are permitted. A psychiatric assessment
  75. 75. LAST REMINDER, NO UNNECESSARY PANIC… ALWAYS COMPLY WITH INFECTION CONTROL & PREVENTION STANDARDS
  76. 76. Sporadic -–-–
  77. 77. SUMMARY ● According to the investigations made for the 148 cases we do not know the source of the infection ( possible animal? Camels, Possible human.. GOK ● Human transmission is there we do not know how? Possible close contact or droplet??? ● Chronic disease is a risk factor specially kidney disease. ●Serological investigation are not yet done but samples are available for testing. ● we will continue surveillance and research.

×